Last reviewed · How we verify
ACE-041
At a glance
| Generic name | ACE-041 |
|---|---|
| Sponsor | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma (PHASE2)
- Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (PHASE1, PHASE2)
- Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (PHASE2)
- Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer (PHASE2)
- Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: